IDEXX Laboratories, Inc. IDXX is well-poised to grow confidence, backed by solid gains in CAG (Companion Animal Group) Diagnostics’ recurring revenues. Strong momentum in the expansion of the ProCyte ...
We expect our H2 organic revenue growth results to benefit by approximately 0.5% overall from equivalent days effects, reflecting approximately 1% organic growth rate benefits in Q3 with limited ...
IDEXX Laboratories, Inc. IDXX is likely to grow in the coming quarters, backed by the sustained success of CAG’s recurring diagnostic products and services. The company’s international business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results